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ABSTRACT
Previous studies suggest that magnesium chloride may have
discriminative stimulus effects that partially overlap with those
of noncompetitive N-methyl-D-aspartate antagonists as well as
certain monoamine uptake inhibitors. In our study, rats were
trained to discriminate 100 mg/kg magnesium chloride from
saline and its discriminative stimulus effects were characterized
with respect to N-methyl-D-aspartate receptor and monoamine
transporter functions in substitution tests. The discriminative
stimulus effects of magnesium chloride were acquired within a
moderate number of training sessions and showed dose-re-
lated substitution after either subcutaneous (3–300 mg/kg) or
intracerebroventricular (0.3–300 mg) administration. The intra-
cerebroventricular administration of magnesium chloride was
over 4000 times more potent than its s.c. administration. The
monoamine uptake inhibitors cocaine, GBR 12909, talsupram
and citalopram fully substituted ($90% magnesium-appropri-
ate responses) for magnesium chloride in the majority of sub-
jects tested and the group averages reached a maximum of 72
to 82% responses on the magnesium-appropriate lever. Based
on relative potency analysis, the rank order of potency of these
four drugs for producing magnesium-appropriate responses
was talsupram 5 cocaine . citalopram 5 GBR 12909. The
N-methyl-D-aspartate receptor antagonists dizocilpine, phen-
cyclidine and NPC 17742 engendered maximum group aver-
ages of 49 to 65% responses on the magnesium-appropriate
lever. The results suggest that the centrally mediated discrim-
inative stimulus effects of magnesium chloride may be more
directly related to interactions with monoamine neurotransmit-
ter functions than to N-methyl-D-aspartate receptor blockade.
Mg11 is a mineral nutrient that is abundant in the brain
as well as in the periphery (Aikawa, 1971). Several pharma-
cological studies have shown that systemically administered
MgCl2 has a profile of behavioral effects that are similar to
those of indirect and direct monoamine receptor agonists.
These include a heightening of aggression and an enhance-
ment of cocaine-induced aggression, apomorphine-induced
sniffing and amphetamine-induced locomotion in mice (Izen-
wasser et al., 1986; Kantak, 1989; Kantak and Adlerstein,
1990). In a mouse conditioned place preference procedure,
MgCl2 was shown to induce a place preference (Lawley and
Kantak, 1990b). Furthermore, MgCl2 and amphetamine, but
not haloperidol or pentobarbital, increased the magnitude of
place preference induced by cocaine (Lawley and Kantak,
1990a). In groups of rats self-administering cocaine under FR
1 or FR 5 schedules of drug delivery, MgCl2 was found to
dose-dependently substitute for cocaine and to maintain a
constant level of drug intake over a 10-day period (Kantak et
al., 1991). MgCl2 also maintained responding above saline
rates in substitution tests conducted under progressive-ratio
schedules of drug delivery in cocaine-trained rats (Kantak et
al., 1991). Progressive-ratio breakpoints, however, were
greater after cocaine availability than they were after MgCl2
availability.
MgCl2 can engender stimulus effects that share some com-
mon features with cocaine and NMDA associated ion channel
blockers. Drug discrimination studies demonstrated that un-
der a 2 mg/kg cocaine training dose condition, MgCl2, as well
as dizocilpine and PCP, engendered full substitution ($90%
responses) for cocaine in the majority of subjects tested (Kan-
tak et al., 1995). These same drugs failed to substitute for
cocaine when subjects were trained to discriminate a higher
dose (10 mg/kg) of cocaine. A competitive NMDA antagonist
did not substitute for cocaine under either training dose
condition. Others also have reported that the NMDA-associ-
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ated channel blockers dizocilpine, PCP and ketamine par-
tially substituted in cocaine-trained rats with a rank order
corresponding to their potency for blocking the NMDA-asso-
ciated ion channel (Koek et al., 1989).
These findings raise the question of whether MgCl2 itself
would have discriminative stimulus effects independent of a
prior drug history. Previous work, for example, has shown
that rats will not self-administer MgCl2 if they had no prior
drug experience (Kantak et al., 1990). However, conditioned
place preference studies demonstrated that MgCl2 could in-
duce a change in preference in drug-naive mice (Lawley and
Kantak, 1990b). The overlap in the behavioral effects of
MgCl2 with those of cocaine and NMDA antagonists de-
scribed above prompted us to characterize the discriminative
stimulus effects of MgCl2 with respect to NMDA receptor and
monoamine transporter functions. Neurochemical studies in-
dicate that Mg11 functions not only as a noncompetitive
NMDA antagonist by blocking the NMDA-associated ion
channel (Wong and Kemp, 1991), but also as an important
cofactor for monamine neurotransmitter binding to trans-
porters (Amejdki-Chab et al., 1992; Hendley et al., 1988;
White, 1975) and receptors (Hamblin and Creese, 1982;
Lefkowitz et al., 1976; Norman et al., 1985; Salama et al.,
1982). Substitution tests were therefore conducted with the
NMDA-associated ion channel blockers dizocilpine and PCP
(Wong and Kemp,1991), the competitive NMDA antagonist
NPC 17742 (Ferkany et al., 1993), the nonselective monoam-
ine uptake inhibitor cocaine (Koe, 1976), the selective DA
uptake inhibitor GBR 12909 (van der Zee et al., 1980), the
selective NE uptake inhibitor talsupram and the selective
5-HT uptake inhibitor citalopram (Hyttel, 1982).
Methods
Subjects. Between experimental sessions, male Wistar rats
(Charles River Breeding Labs, Portage, MI) were housed in individ-
ual stainless steel cages (24 3 18 3 18 cm). Home cages were located
within a temperature- (74 6 4° F) and a light- (0800 hr on, 2000 hr
off) controlled vivarium. All rats were experimentally naive at the
beginning of the study. The rats had continuous access to water in
their home cages. Food (Agway Prolab Rodent Chow, Syracuse, NY)
was restricted to 16 g/day and was provided after daily sessions. This
ration of food maintained body weights at approximately 85% of ad
libitum values. For the study duration, body weights ranged from
275 6 12 to 435 6 9 g in experiments involving substitution with
various monoamine uptake inhibitors and NMDA antagonists and
from 327 6 5 to 478 6 10 g in experiments involving peripheral vs.
central administration of MgCl2.
Apparatus. Each of four identical experimental chambers for rats
(Gerbrands, model A, Waltham, MA) was equipped with two re-
sponse levers that were mounted 7.6 cm apart. A pellet dispenser,
which emitted an audible click when operated, delivered 45 mg food
pellets (Noyes, Traditional Formula, Lancaster, NH) to a receptacle
located between the levers. A sound-attenuating cubicle enclosed
each chamber. In each cubicle, an overhead light provided general
illumination and a fan provided ventilation and masked extraneous
sounds. Experimental events were controlled by a 286 AT-compatible
computer that was programmed in Medstate Notation and connected
to an interface (Med Associates, East Fairfield, VT).
Drugs. The drugs studied were: cocaine hydrochloride and PCP
hydrochloride (NIDA, Rockville, MD), dizocilpine maleate [(1)-MK
801] (Merck, Sharp and Dohme, West Point, PA), NPC 17742 (NOVA
Pharmaceutical Corp., Baltimore, MD), MgCl2 z6H2O (Fisher Scien-
tific, Medford, MA), GBR 12909 dihydrochloride (Research Biochemi-
cals Inc., Natick, MA), citalopram hydrobromide and talsupram hy-
drochloride (Lundbeck A/S, Copenhagen, Denmark). Except as noted
below, drugs were dissolved and diluted to desired concentrations in
either sterile 0.9% saline or sterile distilled water. Doses are ex-
pressed as salts (the anhydrous salt for MgCl2). GBR 12909 (30
mg/ml) was dissolved in 0.9% saline and 1 M acetic acid (8:2), heated
to 55°C and diluted to desired concentrations with 0.9% saline. NPC
17742 (30 mg/ml) was dissolved in 100 mM sodium hydroxide and
diluted to desired concentrations with distilled water. MgCl2 was
either administered s.c. in a volume of 3.0 ml/kg body weight 15 min
before the session (Kantak et al., 1992, 1995) or infused i.c.v. in a
volume of 5 ml over a 5-min period immediately before the session
(Buck et al., 1979; Willetts and Balster, 1988). Rats were gently held
by the experimenter during infusions. The infusion cap was left in
place for one min after the infusion. Other drugs were administered
i.p. 15 min before the session in a volume of 1.0 ml/kg body weight.
Drug discrimination procedure. A total of 14 rats was trained
to discriminate s.c. injections of 100 mg/kg MgCl2 from saline. After
administration of MgCl2, 10 responses (FR 10) on one lever resulted
in delivery of a food pellet, whereas after administration of saline, 10
responses on the other lever produced a food pellet. Training sessions
were conducted daily (Monday to Friday) and lasted for a total of 15
min. Different sequences of randomly assigned saline and drug
training sessions were used for each subject to ensure that any
olfactory cues associated with the two levers would not bias the
discrimination (Extance and Goudie, 1981). The training criteria
consisted of at least 10 consecutive sessions in which $90% of re-
sponses were made on the injection-appropriate lever and the total
number of responses on both levers did not exceed 12 before the first
food pellet was delivered.
Drug testing procedure. Drug test sessions were conducted
once or twice per week, with training sessions scheduled on inter-
vening days. Test sessions were conducted only if performance dur-
ing the preceding training session met the criteria previously de-
scribed. Test sessions were identical to training sessions except that
10 responses on either lever resulted in delivery of a food pellet. In
experiments involving substitution tests with monoamine uptake
inhibitors and NMDA antagonists, a range of doses of s.c. MgCl2
initially was examined in 10 subjects. Next, a range of doses of each
of the four monoamine uptake inhibitors and each of the three
NMDA antagonists was examined in subsets of six subjects to deter-
mine the degree to which each compound substituted for the 100
mg/kg training dose of MgCl2. Most subjects received three or four of
the seven test compounds; two subjects received six of the test
compounds and one subject received all seven test compounds.
Among the test compounds examined in each subject, at least one
was an uptake inhibitor and one was a NMDA antagonist. Drugs
were studied in different orders with different subjects, and saline
test sessions were conducted on two or three occasions in each
subject at various times during the experiment. In experiments
involving peripheral vs. central administration of MgCl2, the remain-
ing subjects were implanted with a chronic indwelling 23-ga. stain-
less steel guide cannula ending 1 mm above the right lateral ventri-
cle of the brain. Before surgery, rats were anesthetized with a
combination of ketamine and xylazine (90 and 10 mg/kg, i.p., respec-
tively). Coordinates for cannula placement were according to the
atlas of Pellegrino et al. (1979): 0.6 mm posterior to bregma, 2.0 mm
lateral from midline and 2.7 mm ventral from the surface of the
skull. A 30-ga. stainless steel stylus was inserted into the guide
cannula between infusions. The rats recovered for 4 days and then
training with s.c. injections resumed. A range of doses of s.c. MgCl2
and saline was subsequently examined in all four subjects. Next, a
range of doses of i.c.v. MgCl2 and saline was examined on two or
three occasions in each subject to determine the degree to which i.c.v.
MgCl2 substituted for the 100 mg/kg training dose of MgCl2.
Analysis of drug effects. The percentage of MgCl2-appropriate
responses was determined for each subject by dividing the number of
MgCl2-associated lever responses by the total number of responses
emitted on both levers. Data were not included in the analysis if less
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than 10 responses were made during a test session. When multiple
determinations were obtained for a particular dose in the same
animal (see above), values were averaged together for individual
subjects before group averages were calculated. Where appropriate,
the dose of a drug estimated to engender 50% MgCl2-appropriate
responses (ED50 6 95% CI) was calculated by linear regression
analysis over the ascending linear portion of the log dose-response
curve. Using Pharmacologic Calculation System software, the log
dose-response curves were further analyzed with the parallel line
assay of Finney (1964) to ascertain differences in potency relative to
MgCl2. In the first study, each mg/kg dose of the test compounds was
first converted to mmol/kg to account for differences in their molec-
ular weights. In the second study, the relative potency between s.c.
and i.c.v. MgCl2 was computed after converting mg/kg s.c. MgCl2 to
mg/rat. For purposes of this study, full substitution for MgCl2 was
defined as $90% MgCl2-appropriate responses.
Rates of responding were calculated for each subject by dividing
the total number of responses on both levers by the total session
length. The response-rate data were analyzed by a single-factor
ANOVA and by post-hoc Dunnett’s tests to compare the response
rates after different doses with the rates after vehicle injections.
Results
Discrimination acquisition and effects of s.c. admin-
istered MgCl2. The 10 rats used in this study met the
training criteria after an average of 35 6 2 training sessions
(range 19–40 sessions). At criteria, rats made an average of
99% 6 0.3 responses on the MgCl2-appropriate lever after
injections of 100 mg/kg MgCl2 and 98% 6 0.6 responses on
the saline-appropriate lever after injections of saline.
Throughout training, the rate of responding was slightly
lower after MgCl2 injections (.84 6 .01 responses per second)
than after saline injections (1.1 6 .01 responses per second).
In substitution tests, MgCl2 (3–300 mg/kg) engendered
dose-related increases in the percentage of MgCl2-appropri-
ate responses. There was full substitution ($90% MgCl2-
appropriate responses) in all subjects after administration of
doses that were equal to or greater than the training dose
(fig. 1, top panel). Regression analysis over the linear portion
of the MgCl2 dose-response curve revealed an ED50 5 20.4
mg/kg (95% CI 5 6.3–66.1). Doses of MgCl2 up to 30 mg/kg
had little or no effect on the response rate compared to the
saline control (fig. 1, bottom panel). Consistent with the
training data, doses of MgCl2 that were $100 mg/kg reduced
the response rate significantly (P , .05).
Substitution tests with monoamine uptake inhibi-
tors. Dose-related increases in the percentage of MgCl2-
appropriate responses (fig. 2, top panel) were engendered by
0.3 to 10.0 mg/kg cocaine, 3.0 to 17.8 mg/kg GBR 12909, 0.1
to 5.6 mg/kg talsupram and 1.0 to 10 mg/kg citalopram. Full
substitution for MgCl2 was observed in all six subjects after
one or more doses of cocaine in the range of 1.0 to 10.0 mg/kg.
For the group of six rats, the average percentage of MgCl2-
appropriate responses reached a maximum of 82% after 3.0
mg/kg cocaine and was 50% after 10.0 mg/kg cocaine. One or
more doses of GBR 12909 engendered full substitution for
MgCl2 in five of six subjects in the dose range of 3.0 to 17.8
mg/kg. Averaged for the group of rats, the maximum percent-
age of MgCl2-appropriate responses reached 74% after 17.8
mg/kg GBR 12909. One or more doses of talsupram also
engendered full substitution for MgCl2 in five of the six
subjects in the dose range of 0.1 to 5.6 mg/kg. For the group
of six rats, the maximum average percentage of MgCl2-ap-
propriate responses reached 72% after 5.6 mg/kg talsupram.
Finally, full substitution for MgCl2 was observed in five of
the six subjects after citalopram in the dose range of 3.0 to
10.0 mg/kg. The maximum average percentage of MgCl2-
appropriate responses reached 82% after 10.0 mg/kg citalo-
pram for the group of six rats. Based on ED50 and relative
potency analysis (table 1), the rank order of potency of these
drugs for producing MgCl2-appropriate responses was talsu-
pram 5 cocaine . citalopram 5 GBR 12909 . MgCl2. Each
monoamine uptake inhibitor, except cocaine, produced dose-
related decreases in the response rate, with significant (P ,
.05) reductions in the rate after the highest doses tested (fig.
2, bottom panel).
Substitution tests with NMDA antagonists. Adminis-
tration of 0.03 to 0.18 mg/kg dizocilpine and 0.3 to 3.0 mg/kg
PCP resulted in dose-related changes in the percentage of
MgCl2-appropriate responses (fig. 3, top). Full substitution
for MgCl2 was observed in three of six subjects after one or
Fig. 1. Effects of MgCl2 in rats trained to discriminate 100 mg/kg
MgCl2 from saline. Abscissae: dose, log scale; ordinates: percentage of
responses on the MgCl2-appropriate lever (top panel) and rate of re-
sponding (bottom panel). Points are the means (6 S.E.M.) based on 10
rats, except as noted. The numbers above each point refer to the
proportion of rats that made $90% MgCl2-appropriate responses after
administration of the dose indicated on the abscissa. Points above S
show the effects of saline.
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more doses of dizocilpine in the range of 0.056 to 0.18 mg/kg.
The maximum average percentage of MgCl2-appropriate re-
sponses reached 50% after 0.1 mg/kg dizocilpine for the group
of six rats. One or more doses of PCP in the range of 1.0 to 3.0
mg/kg engendered full substitution for MgCl2 in four of six
subjects and the maximum average percentage of MgCl2-
appropriate responses reached 65% after 1.0 mg/kg PCP for
the group of six rats. The competitive NMDA antagonist NPC
17742 (0.3–30 mg/kg) did not produce any dose-related
change in the percentage of MgCl2-appropriate responses
(fig. 3, top). Responses were mainly made on the saline-
associated lever in most animals after each dose of NPC
17742. The average percentage of MgCl2-appropriate re-
sponses was 49% or less across the range of doses for the
group of rats. Although NPC 17742 produced full substitu-
tion for MgCl2 in four of six subjects, its occurrence was
irregularly related to dose (between 0.3–17.8 mg/kg for indi-
vidual animals). As shown in the bottom of figure 3, each
NMDA antagonist produced dose-related decreases in the
response rate, with significant (P , .05) reductions in the
rate after the two highest doses tested.
Effects of peripherally vs. centrally administered
MgCl2. In experiments involving s.c. vs. i.c.v. injections of
MgCl2, the rats met the training criteria after an average of
46 6 4 training sessions (range 24–57 sessions). After train-
ing, s.c. injections of MgCl2 (3–178 mg/kg) engendered dose-
related increases in the percentage of MgCl2-appropriate re-
sponses, with an ED50 5 31.6 mg/kg (95% CI 5 15.1–66.1).
Full substitution was observed in all subjects after doses that
were equal to or greater than the training dose (fig. 4, top
left). These results are quite similar to those reported in
figure 1.
Administration of i.c.v. MgCl2 (0.3–300 mg) engendered
dose-related, biphasic changes in the percentage of MgCl2-
appropriate responses (fig. 4, top right). Full substitution for
the s.c. administration of 100 mg/kg MgCl2 was observed in
all subjects after 30 mg MgCl2 and in three of the four sub-
jects after 100 mg MgCl2. The administration of 300 mg MgCl2
resulted in much less MgCl2-appropriate responses in all
subjects. Based on ED50 and relative potency analyses over
the linear ascending portion of the log dose-response curve,
the i.c.v. administration of MgCl2 was more than 4000 times
more potent than the s.c. administration of MgCl2 for pro-
ducing MgCl2-appropriate responses (table 1). The response
rates were not significantly altered by any dose of i.c.v. ad-
Fig. 2. Effects of cocaine, GBR 12909, talsupram and citalopram in
rats trained to discriminate 100 mg/kg MgCl2 from saline. Points are the
means (6 S.E.M.) based on six rats, except as noted. Saline values and
other details are as in figure 1.
Fig. 3. Effects of dizocilpine, PCP and NPC 17742 in rats trained to
discriminate 100 mg/kg MgCl2 from saline. Points are the means (6
S.E.M.) based on six rats, except as noted. Saline values and other
details are as in figure 1.
TABLE 1
ED50 and relative potency (95% CI range) for producing MgCl2-
appropriate responses after substitution tests with cocaine and







MgCl2 20.4 215 1.0
Cocaine 1.4 4.1 0.014 0.005–0.030
Talsupram 0.7 2.0 0.008 0.001–0.025
Citalopram 4.6 11.4 0.048 0.019–0.125






s.c. MgCl2 31.6 13,490 1.0
i.c.v. MgCl2 3.4 2.4 3 10
24 0.9 3 1024–6 3 1024
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ministered MgCl2 (fig. 4, bottom right), although a rate-
decreasing effect was evident in some rats after 300 mg. As
were reported in figure 1, the response rates were signifi-
cantly decreased (P , .05) after doses that were $ 100 mg/kg
s.c. MgCl2 (fig. 4, bottom left).
Discussion
Our results indicate that MgCl2 has discriminative stimu-
lus effects that were reproducibly acquired and involved cen-
tral mechanisms. Furthermore, the discriminative stimulus
effects of MgCl2 were less similar to other drugs with NMDA
antagonist effects and more similar to monoamine uptake
inhibitors. After a moderate number of training sessions, 100
to 300 mg/kg MgCl2 fully substituted for the 100 mg/kg
training dose. Lower doses engendered fewer responses on
the MgCl2-appropriate lever. The S-shaped dose-response
function that resulted from training rats to discriminate 100
mg/kg MgCl2 is a general feature of most drugs having dis-
criminative stimulus effects (see Jarbe, 1989 for review).
An important question that can be raised relates to the
pharmacological specificity of the discriminative stimulus
effects of MgCl2. Because the concentration of the 100 mg/kg
training dose was 350 mM, it is possible that the solution’s
hypertonicity rather than its pharmacological properties
caused the cuing effects of MgCl2. Controls for hypertonicity
were not used as part of our experiments. Arguments against
this possibility include the fact that the 30 mg solution was
hypotonic (62.5 mM), yet its i.c.v. infusion fully substituted
for the 100 mg/kg training dose. Other studies have shown
that the i.v. delivery of hypertonic (335 mM) NaCl did not
alter self-administration responding any differently than
physiological (154 mM) NaCl (Kantak et al., 1990; 1991).
Furthermore, the differential effects of the NMDA-associated
ion channel blockers vs. monoamine uptake inhibitors and
the relatively weak effects of NPC 17742 in substitution tests
suggest some degree of pharmacological specificity to the
discriminative stimulus effects of MgCl2 (Colpaert et al.,
1979; Terry et al., 1994).
The biphasic, dose-related changes in drug-appropriate re-
sponses after i.c.v. administration of MgCl2 have generally
not been observed after the i.c.v. administration of other
drugs (e.g., Sannerud et al., 1991; Willetts and Balster, 1988;
Wood et al., 1987). In these other studies, the dose-related
changes in drug-appropriate responses tended to be linear. In
our study, drug-appropriate responses were linearly related
to MgCl2 dose, up to 100 mg. The i.c.v. infusion of our highest
dose of MgCl2 (300 mg) resulted in much less MgCl2-appro-
priate responses than lower doses (30 or 100 mg). The effects
of 300 mg MgCl2 were most likely nonspecific, which could be
related to a severe depression of cortical neurons that is
produced by high concentrations of centrally applied Mg11
ions (Kelly et al., 1969).
In other drug discrimination studies, i.c.v. infusions of 80
mg cocaine (Wood et al., 1987), 150 mg PCP (Willetts and
Balster, 1988) and 44 mg midazolam (Sannerud et al., 1991)
fully substituted for their systemic injections, suggesting
central mediation of their discriminative stimulus effects.
Furthermore, the potency of these drugs was up to 40-fold
greater after direct infusion into the lateral ventricle of the
brain. From comparing s.c. and i.c.v. administration of
MgCl2, it is apparent that all doses of i.c.v. administered
MgCl2 studied would have engendered saline-appropriate
responses if systemically administered. Therefore, diffusion
out of the brain could not have accounted for the full substi-
tution by 30 mg i.c.v. MgCl2 for the 100 mg/kg s.c. training
dose. The i.c.v. administration of 17 and 50 mg MgCl2 has
previously been shown to increase CSF concentrations of
Mg11 by 2- and 6-fold, respectively, and to dose-dependently
decrease audiogenic seizure severity in rats without altering
serum concentrations of Mg11 (Buck et al., 1979).
Although cannulae placements were not verified in this
study, central mediation of the discriminative stimulus ef-
fects of MgCl2 also is suggested by the finding that MgCl2
was more than 4000 times more potent after its central vs.
peripheral administration. The greater increase in potency
after direct infusion of MgCl2 into the lateral ventricle of the
brain compared to other drugs (Sannerud et al., 1991; Wil-
letts and Balster, 1988; Wood et al., 1987) may be related to
the fact that only small amounts of MgCl2 are absorbed and
distributed in the brain after its peripheral administration
(Hilmy and Somjen, 1968), yet central neurons are quite
sensitive to a relatively small concentration (1 mM) of ionto-
phoretically applied Mg11 (Somjen and Kato, 1968). This
may account for the relatively large dose of MgCl2 (100 mg/kg
or an average of 44,000 mg/rat) necessary for maintaining
discriminative stimulus control after a s.c. injection and the
relatively small dose of MgCl2 (30 mg) necessary for full
substitution after infusion into the lateral ventricle of the
brain.
Among its biochemical effects in the brain, Mg11 functions
as a noncompetitive NMDA antagonist by binding to a spe-
Fig. 4. Effects of s.c. MgCl2 (left) and i.c.v. MgCl2 (right) in rats trained
to discriminate 100 mg/kg MgCl2 from saline. Points are the means (6
S.E.M.) based on four rats. Other details are as in figure 1.
204 Kantak et al. Vol. 283
cific Mg11 recognition site and blocking the NMDA-associ-
ated ion channel (Wong and Kemp, 1991). However, the
results of our study suggest that the discriminative stimulus
effects of MgCl2 were distinct from other NMDA antagonists.
The NMDA-associated ion channel blockers PCP and dizo-
cilpine only partially substituted for MgCl2. The MgCl2-like
effects of NPC 17742 were weak and not systematically re-
lated to dose. Responses were mostly made on the saline-
associated lever over the entire dose range. A previous study
in PCP-trained rats demonstrated that 80 mg/kg MgCl2 en-
gendered only 21% PCP-appropriate responses, yet the rate
of responding was significantly decreased, suggesting that a
behaviorally effective dose of MgCl2 was used (Jortani et al.,
1992). In other studies, a competitive NMDA antagonist did
not substitute for PCP (Willetts and Balster, 1988) and PCP
did not substitute for a competitive NMDA antagonist (Wil-
letts et al., 1989). Taken together, these findings show that
the discriminative stimulus effects of MgCl2 do not com-
pletely overlap with those of other NMDA-associated ion
channel blockers or competitive NMDA antagonists, which
also do not completely overlap with each other.
The discriminative stimulus effects of MgCl2 do appear to
overlap with the nonselective monoamine uptake inhibitor
cocaine and the selective monoamine uptake inhibitors GBR
12909, talsupram and citalopram. The nonselective monoam-
ine uptake inhibitor cocaine engendered 82% MgCl2-appro-
priate responses after a dose of 3 mg/kg. These results are
consistent with the study showing that 30 to 300 mg/kg
MgCl2 engendered 73 to 96% cocaine-appropriate responses
in rats trained to discriminate 2 mg/kg cocaine (Kantak et al.,
1995). The selective DA, NE and 5-HT uptake inhibitors fully
substituted for MgCl2 in most animals and engendered a
higher degree of MgCl2-appropriate responses than the
NMDA antagonists. These findings suggest that the discrim-
inative stimulus effects of MgCl2 may involve more than its
neurochemical effect at the NMDA receptor. Indeed, Mg11
has multiple biochemical sites of action in the brain (Ebel
and Gunther, 1980). The discriminative stimulus effects of
MgCl2 could involve interactions of MgCl2 at either monoam-
ine uptake sites, by inhibiting monoamine transporter func-
tions, or monoamine receptor sites, by increasing monoamine
binding and receptor activation. Although low mM concen-
trations of Mg11 are necessary for maintaining normal rates
of monoamine uptake (e.g., Amejdki-Chab et al., 1992; Hend-
ley et al., 1988; White, 1975), Mg11 concentrations of more
than 10 mM can inhibit the uptake of DA and reduce specific
binding of [3H]GBR 12783 or [3H]GBR 12935 with an IC50
value of 16 mM (Amejdki-Chab et al., 1992; Janowsky et al.,
1986). From the i.c.v. infusion of 30 mg MgCl2, which fully
substituted for the 100 mg/kg training dose, the concentra-
tion of MgCl2 delivered to the lateral ventricle was 62.5 mM.
This concentration would be diluted at least 100-fold after
the distribution of MgCl2 into brain tissue. If DA, NE and
5-HT transporters are similarly inhibited by concentrations
of Mg11 of more than 10 mM in vivo, then the concentration
of MgCl2, either from s.c. injections or i.c.v. infusions, may
not have reached high enough levels to inhibit monoamine
transporter functions in brain tissue.
Mg11 has been shown to be necessary for the binding of
monoamine neurotransmitters at D1, D2, a2-NE, b-NE and
5-HT1a receptors (e.g., Hamblin and Creese, 1982; Lefkowitz
et al., 1976; Norman et al., 1985; Salama et al., 1982). Dopa-
mine binding studies, for example, have demonstrated that
Mg11 increases the Bmax associated with
3H-spiroperidol
binding in rat striata by 200% above control (Usdin et al.,
1980). This increase is seen with concentrations of Mg11 as
low as 0.1 to 1.0 mM. Mg11 does not actually increase the
number of receptors, but prevents the time-dependent deg-
radation of ligand binding to the receptor. Other studies (De
Vries and Beart, 1985; Hamblin and Creese, 1982) demon-
strated that Mg11 enhances DA affinity at D2 receptors by a
factor of 1000 (a mM to nM potency change). Given that the
monoamine uptake inhibitors used in our study could be
regarded as indirect monoamine receptor agonists, it is more
likely that monoamine receptor activation, rather than
monoamine uptake inhibition, could be the common mecha-
nism by which MgCl2, cocaine, GBR 12909, talsupram and
citalopram engendered a high degree of MgCl2-appropriate
responses. Further characterization of the discriminative
stimulus effects of MgCl2 should include antagonism studies
with NMDA and selective monoamine receptor blockers to
evaluate the role of the Mg11 site on the NMDA receptor
complex vs. monoamine receptor activation in mediating the
effects of MgCl2. Furthermore, NE mechanisms may be par-
ticularly important for the discriminative stimulus effects of
MgCl2. The potency of talsupram was equal to that of cocaine
and more than that of citalopram and GBR 12909 in engen-
dering MgCl2-appropriate responses. Interestingly, as with
MgCl2 (Kantak et al., 1995), selective NE uptake inhibitors
engendered cocaine-appropriate responses under a low-dose,
but not a high-dose, training condition (Spealman, 1995;
Terry et al., 1994). To eliminate any pharmacokinetic differ-
ences among talsupram, cocaine, citalopram and GBR 12909,
additional substitution studies with the i.c.v. administration
of these uptake inhibitors should also be conducted to deter-
mine if talsupram is still the most potent in engendering
MgCl2-appropriate responses. If the rank order of potency is
the same in this context as it was when these drugs were
given systemically, then these potency differences would in-
dicate a predominance of NE mechanisms in discriminative
stimulus effects of MgCl2.
In summary, the discriminative stimulus effects of MgCl2
are novel findings and add to the growing evidence that
MgCl2 can have pharmacological effects (e.g., Buck et al.,
1979; Kantak et al., 1992; 1995; McIntosh et al., 1989; Smith
et al., 1993). The discriminative stimulus effects of MgCl2
appear to be centrally mediated and may involve interactions
of MgCl2 at monoamine receptor sites.
Acknowledgments
The authors thank Dr. Roger D. Spealman for his comments on the
manuscript. We also thank NIDA and Nova Pharmaceutical Corpo-
ration for generously providing some drugs used in these studies.
References
AIKAWA, J. K.: The biochemical and cellular functions of magnesium. In First
International Symposium on Magnesium Deficit in Human Pathology, ed. by
J. Durlach, pp. 39–53, Villel, France, 1971.
AMEJDKI-CHAB, N., BENMANSOUR, S., COSTENTIN, J. AND BONNET, J.-J.: Effects of
several cations on the neuronal uptake of dopamine and the specific binding
of [3H]GBR 12783: Attempts to characterize the Na1 dependence of the
neuronal transport of dopamine. J. Neurochem. 59: 1795–1804, 1992.
BUCK, D. R., MAHONEY, A. W. AND HENDRICKS, D. G.: Effects of cerebral intra-
ventricular magnesium injections and a low magnesium diet on nonspecific
excitability level, audiogenic seizure susceptibility and serotonin. Pharma-
col. Biochem. Behav. 10: 487–491, 1979.
COLPAERT, F. C., NIEMEGEERS, C. J. E. AND JANSSEN, P. A. J.: Discriminative
stimulus properties of cocaine: Neuropharmacological characteristics as de-
1997 DS Effects of MgCl2 205
rived from stimulus generalization experiments. Pharmacol. Biochem. Be-
hav. 10: 535–546, 1979.
DE VRIES, D. J. AND BEART, P. M.: Magnesium ions reveal nanomolar potency of
dopamine at [3H]spiperone labelled D-2 receptors in rat corpus striatum.
Eur. J. Pharmacol. 109: 417–419, 1985.
EBEL, H. AND GUNTHER, T.: Magnesium metabolism: A review. J. Clin. Chem.
Clin. Biochem. 8: 257–270, 1980.
EXTANCE, K. AND GOUDIE, A. J.: Inter-animal olfactory cues in operant drug
discrimination procedures in rats. Psychopharmacology 73: 363–371, 1981.
FERKANY, J. W., HAMILTON, G. S., PATCH, R. J., HUANG, Z., BOROSKY, S. A.,
BEDNAR, D. L., JONES, B. E., ZUBROWSKI, R., WILLETS, J. AND KARBON, E. W.:
Pharmacological profile of NPC 17742 [2R,4R,5S-(2-amino-4,5- (1,2-
cyclohexyl)-7-phosphonoheptanoic acid)], a potent, selective and competitive
N-methyl-D-aspartate receptor antagonist. J. Pharmacol. Exp. Ther. 264:
256–264, 1993.
FINNEY, D. J.: Statistical Methods in Biological Assay, 2nd ed., Hafner, New
York, 1964.
HAMBLIN, M. W. AND CREESE, I.: 3H-Dopamine binding to rat striatal D-2 and
D-3 sites: Enhancement by magnesium and inhibition by guanine nucleo-
tides and sodium. Life Sci. 30: 1587–1595, 1982.
HENDLEY, E. D., WHITTEMORE, S. R., CHAFFEE, J. E. AND EHRLICK, Y. H.: Regu-
lation of norepinephrine uptake by adenine nucleotides and divalent cations:
Role for extracellular protein phosphorylation. J. Neurochem. 50: 263–273,
1988.
HILMY, M. I. AND SOMJEN, G. G.: Distribution and tissue uptake of magnesium
related to its pharmacological effects. Am. J. Physiol. 214: 406–413, 1968.
HYTTEL, J.: Citalopram–Pharmacological profile of a specific serotonin uptake
inhibitor with antidepressant activity. Prog. Neuropsychopharmacol. Biol.
Psychiatry 6: 277–295, 1982.
IZENWASSER, S. E., GARCIA-VALDEZ, K. AND KANTAK, K. M.: Stimulant-like effects
of magnesium on aggression in mice. Pharmacol. Biochem. Behav. 25: 1195–
1199, 1986.
JANOWSKY, A., BERGER, P., VOCCI, F., LABARCA, R., SKOLNICK, P. AND PAUL, S. M.:
Characterization of sodium-dependent [3H]GBR-12935 binding in brain: A
radioligand for selective labelling of the dopamine transport complex.
J. Neurochem. 46: 1272–1276, 1986.
JARBE, T. U. C.: Discrimination learning with drug stimuli: Methods and
applications. In Neuromethods: Psychopharmacology, vol. 13, ed. by A. A.
Boulton, G. B. Baker and A. J. Greenshaw, pp. 513–563, Humana Press,
Clifton, NJ, 1989.
JORTANI, S. A., WILLETTS, J. AND BALSTER, R. L.: Systemic magnesium chloride
administration fails to produce phencyclidine-like discriminative stimulus
effects in rats. Neurosci. Lett. 135: 136–138, 1992.
KANTAK, K. M., BOURG, J. F. AND LAWLEY, S. I.: Failure of magnesium to
maintain self-administration in cocaine-naive rats. Pharmacol. Biochem.
Behav. 36: 9–12, 1990.
KANTAK, K. M., EDWARDS, M. A. AND SPEALMAN, R. D.: Effects of N-methyl-D-
aspartate antagonists in rats discriminating different doses of cocaine: com-
parison with direct and indirect dopamine agonists. J. Pharmacol. Exp.
Ther. 274: 657–665, 1995.
KANTAK, K. M., LAWLEY, S. I., WASSERMAN, S. J. AND BOURG, J. F.: Magnesium-
maintained self-administration responding in cocaine-trained rats. Psycho-
pharmacology 104: 527–535, 1991.
KANTAK, K. M. AND ADLERSTEIN, L. K.: Enhancement of apomorphine and
l-amphetamine induced behaviors by magnesium. Pharmacol. Biochem. Be-
hav. 36: 29–33, 1990.
KANTAK, K. M., WASSERMAN, S. J., LAWLEY, S. I. AND O’CONNOR, T.: Acute and
multiple injection effects of MgCl2 on responding maintained by cocaine,
extinction from cocaine, glucose 1 saccharin, and food. Pharmacol. Biochem.
Behav. 41: 415–423, 1992.
KANTAK, K. M.: Magnesium alters the potency of cocaine and haloperidol on
mouse aggression. Psychopharmacology 99: 181–188, 1989.
KELLY, J. S., KRNJEVIC, K. AND SOMJEN, G. G.: Divalent cations and electrical
properties of cortical cells. J. Neurobiol. 2: 197–208, 1969.
KOEK, W., COLPAERT, F. C., WOODS, J. H. AND KAMENKA, J.-M.: The phencyclidine
(PCP) analog N-[1-(2-benzo(B)thiophenyl)cyclohexyl] piperidine shares co-
caine-like but not other characteristic behavioral effects with PCP, ketamine
and MK-801. J. Pharmacol. Exp. Ther. 250: 1019–1027, 1989.
KOE, B. K.: Molecular geometry of inhibitors of the uptake of catecholamines
and serotonin in synaptosomal preparations of rat brain. J. Pharmacol. Exp.
Ther. 199: 649–661, 1976.
LAWLEY, S. I. AND KANTAK, K. M.: Post-conditioning effects of magnesium on
cocaine induced place preference in mice. Pharmacol. Biochem. Behav. 36:
531–538, 1990a.
LAWLEY, S. I. AND KANTAK, K. M.: Magnesium induced place preference in mice.
Pharmacol. Biochem. Behav. 36: 539–545, 1990b.
LEFKOWITZ, R. J., MULLIKIN, D. AND CARON, M. G.: Regulation of b-adrenergic
receptors by guanyl-59-yl imidodiphosphate and other purine nucleotides.
J. Biol. Chem. 15: 4686–4692, 1976.
MCINTOSH, T. K., VINK, R., YAMAKAMI, I. AND FADEN, A. I.: Magnesium protects
against neurological deficit after brain injury. Brain Res. 482: 252–260,
1989.
NORMAN, A. B., BATTAGLIA, G. AND CREESE, I.: [3H]WB4101 labels the 5-HT1a
serotonin receptor subtype in rat brain: Guanine nucleotide and divalent
cation sensitivity. Mol. Pharmacol. 28: 487–494, 1985.
PELLEGRINO, L. J., PELLEGRINO, A. S. AND CUSHMAN, A. J.: A Stereotaxic Atlas of
the Rat Brain, 2nd ed., Plenum Press, New York, 1979.
SALAMA, A. I., LIN, L. L., REPP, L. D. AND U’PRICHARD, D. C.: Magnesium reduces
affinities of antagonists at rat cortex a2-adrenergic receptors labelled with
3H-clonidine: Evidence for heterogeneity of a2-receptor conformations with
respect to antagonists. Life Sci. 30: 1305–1311, 1982.
SANNERUD, C. A., ATOR, N. A. AND GRIFFITHS, R. R.: Comparison of the discrim-
inative stimulus effects of midazolam after intracranial and peripheral
administration in the rat. Life Sci. 49: 261–268, 1991.
SMITH, D. H., OKIYAMA, K., GENNARELLI, T. A. AND MCINTOSH, T. K.: Magnesium
and ketamine attenuate cognitive dysfunction following experimental brain
injury. Neurosci. Lett. 157: 211–214, 1993.
SOMJEN, G. G. AND KATO, G.: Effects of magnesium and calcium on neurones in
the central nervous system. Brain Res. 9: 161–164, 1968.
SPEALMAN, R. D.: Noradrenergic involvement in the discriminative stimulus
effects of cocaine in squirrel monkeys. J. Pharmacol. Exp. Ther. 275: 53–62,
1995.
TERRY, P., WITKIN, J. M. AND KATZ, J. L.: Pharmacological characterization of
the novel discriminative stimulus effects of a low dose of cocaine. J. Phar-
macol. Exp. Ther. 270: 1041–1048, 1994.
USDIN, T. B., CREESE, I. AND SNYDER, S. H.: Regulation by cations of [3H]spiro-
peridol binding associated with dopamine receptors of rat brain. J. Neuro-
chem. 34: 669–676, 1980.
VAN DER ZEE, P., KOGER, H. S., GOOTJES, J. AND HESPE, W.: Aryl 1,4-dialk(en)yl-
piperazines as selective and very potent inhibitors of dopamine uptake. Eur.
J. Med. Chem. 15: 363–370, 1980.
WHITE, T. D.: A role of divalent cations in the uptake of noradrenaline by
synaptosomes. J. Neurochem. 24: 1037–1042, 1975.
WILLETTS, J., BOBELIS, D. J. AND BALSTER, R. L.: Drug discrimination based on
the competitive N-methyl-D-aspartate antagonist NPC 12626. Psychophar-
macology 99: 458–462, 1989.
WILLETTS, J. AND BALSTER, R. L.: The discriminative stimulus effects of N-
methyl-D-aspartate antagonists in phencyclidine-trained rats. Neurophar-
macology 27: 1249–1256, 1988.
WONG, E. H. F. AND KEMP, J. A.: Sites for antagonism of the N-methyl-D-
aspartate receptor channel complex. Annu. Rev. Pharmacol. Toxicol. 31:
401–425, 1991.
WOOD, D. M., RETZ, K. R. AND EMMETT-OGLESBY, M. W.: Evidence of a central
mechanism mediating tolerance to the discriminative stimulus properties of
cocaine. Pharmacol. Biochem. Behav. 28: 401–406, 1987.
Send reprint requests to: Dr. Kathleen M. Kantak, Department of Psychol-
ogy, Boston University, 64 Cummington Street, Boston, MA 02215.
206 Kantak et al. Vol. 283
